Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial
EuroIntervention · 2024-10 · 20 (20) · e1309-e1318
DOI: 10.4244/eij-d-24-00203 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2024-10. Verfasst von Zuzana Motovska und 37 weiteren Autor:innen. Beteiligte Einrichtung: Cardiocentre, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Myocardial Infarction, Platelet Aggregation Inhibitors, Shock, Cardiogenic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiocentre, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- First Department of Internal Medicine - Cardioangiology, ICRC, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
- CINRE, Bratislava, Slovak Republic.
- Cardiovascular Department, University Hospital Ostrava and Faculty of Medicine, University Ostrava, Ostrava, Czech Republic.
- Department of Internal Medicine and Cardiology, Faculty of Medicine of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- Department of Cardiology and Angiology, University Hospital/Eberhard Karls University, Tübingen, Germany.
Zitieren
APA
Motovska, Z., Hlinomaz, O., Mrozek, J., Kala, P., Geisler, T., Hromadka, M., Akin, I., Precek, J., Kettner, J., Cervinka, P., Montalescot, G., Jarkovsky, J., Belohlavek, J., Bis, J., Matejka, J., Vodzinska, A., Muzafarova, T., Tomasov, P., Schee, A., …, & Group, D. S. (2024). Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention, 20(20), e1309-e1318. https://doi.org/10.4244/eij-d-24-00203
Vancouver
Motovska Z, Hlinomaz O, Mrozek J, Kala P, Geisler T, Hromadka M, et al. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention. 2024;20(20):e1309-e1318. doi:10.4244/eij-d-24-00203
BibTeX
@article{Motovska2024,
author = {Motovska, Zuzana and Hlinomaz, Ota and Mrozek, Jan and Kala, Petr and Geisler, Tobias and Hromadka, Milan and Akin, Ibrahim and Precek, Jan and Kettner, Jiri and Cervinka, Pavel and Montalescot, Gilles and Jarkovsky, Jiri and Belohlavek, Jan and Bis, Josef and Matejka, Jan and Vodzinska, Alexandra and Muzafarova, Tamilla and Tomasov, Pavol and Schee, Alexander and Bartus, Stanislav and Andrasova, Andrea and Olivier, Christoph B and Kovarik, Ales and Ostadal, Petr and Demlova, Regina and Souckova, Lenka and Vulev, Ivan and Coufal, Zdeněk and Kochman, Janusz and Marinov, Iuri and Kubica, Jacek and Ducrocq, Gregory and Karpisek, Michal and Klimsa, Zdenek and Hudec, Martin and Widimsky, Petr and Bhatt, Deepak L and Group, Dapt-Shockami Study},
title = {Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial},
journal = {EuroIntervention},
year = {2024},
volume = {20},
number = {20},
pages = {e1309--e1318},
doi = {10.4244/eij-d-24-00203}
}
EUVIMED